Title page

Autoimmune Thyroid Disease Correlates to Islet Autoimmunity on Zinc Transporter 8

Autoantibody: A Cross-section Study

Yun Cai¹*, Jieni Yan¹*, Yong Gu¹, Heng Chen¹, Qingfang Hu¹, Yang Chen¹, Zhixiao Wang¹,
Xiaoyun Liu¹, Huanhuan Chen¹, Xinyu Xu¹, Mei Zhang¹,Liping Yu², Xuqin Zheng ¹Δ, Tao
Yang¹Δ

1 Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University,
Nanjing, Jiangsu, China;
2 Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, CO,
USA.

* These authors contributed equally to this work.

Δ Corresponding author and person to whom reprint requests should be addressed:
Xuqin Zheng, E-mail: zhengxuqin@njmu.edu.cn
Tao Yang, E-mail: yangt@njmu.edu.cn

Department of Endocrinology, the First Affiliated Hospital of Nanjing Medical University,
300 Guangzhou Road, Nanjing, 210029, Jiangsu, China
Tel/Fax: 86-25-83781781
Abstract

**Background:** The most common coexisting organ-specific autoimmune disease in patients with Type 1 diabetes mellitus (T1DM) is autoimmune thyroid disease (AITD). Many studies have showed prevalence rate of thyroid autoantibodies range from 3.7-35% in T1DM patients, while some of them suggested the associations between thyroid autoantibodies and islet autoantibodies. However, little work has been done about the anti-islet autoimmune status in patients with autoimmune thyroid disease (AITD), and so far there have been no clinical report based on large population about zinc transporter 8 autoantibody (ZnT8A) in patients with AITD. We aimed to explore the presence of islet autoantibodies, ZnT8A, glutamic acid decarboxylase autoantibodies (GADA) and tyrosine phosphatase autoantibodies (IA-2A) compared with thyroid autoantibodies, thyroid peroxidase autoantibodies (TPOAb) and thyroglobulin autoantibodies (TGAb) and thyrotropin receptor autoantibodies (TRAb) in AITD patients.

**Methods:** In total 740 AITD patients, 108 type 1 diabetes mellitus (T1DM) patients with AITD, 172 non-autoimmune thyroid disease (nAITD) patients and 115 healthy controls were recruited in the cross-sectional study. Islet autoantibodies, ZnT8A, GADA, IA-2A and thyroid autoantibodies, TPOAb, TGAb, TRAb were detected with Radioimmunoassay and Chemiluminescence. Islet autoantibody relative value was established to compare the distribution of the three islet autoantibodies.

**Results:** The prevalence of ZnT8A and GADA in AITD group was significantly higher than that in healthy controls (ZnT8A: 15.00% vs 1.74%, GADA: 7.97% vs 0.87%, both P<0.05). Similarly, the prevalence of IA-2A in AITD group was higher than that in healthy controls (4.19% vs 0%, P<0.05). However, any islet autoantibodies positive rate in AITD group was significantly lower than that in T1DM with AITD group. Analysis of multivariable linear
regression suggested that ZnT8A relative value was positively related with GADA relative value ($\beta=0.352$, $P<0.01$) and TPOAb titer ($\beta=0.002$, $P<0.01$), and GADA relative value was also positively related with ZnT8A relative value ($\beta=0.183$, $P<0.01$).

**Conclusions:** An increased prevalence of ZnT8A as well as a relatively high prevalence of islet autoimmunity was found in AITD patients, indicating that there is a potential link between thyroid autoimmunity and islet autoimmunity.

**Trial registration:** Retrospectively registered.

**Keywords**

autoimmune thyroid disease, type 1 diabetes mellitus, zinc transporter 8 autoantibody, thyroid peroxidase autoantibodies

---

**Background**

Autoimmune thyroid disease (AITD) is a common organ-specific autoimmune disorder which includes two main clinical presentations: Graves’ disease and Hashimoto’s thyroiditis. Both Graves’ disease and Hashimoto’s thyroiditis share the immunologic feature of the presence of circulating autoantibodies such as thyrotropin receptor autoantibodies (TRAb), thyroid peroxidase autoantibodies (TPOAb) and thyroglobulin autoantibodies (TGAb). TRAb occur predominantly in Graves’ disease and play a key role in Graves’ hyperthyroidism, while TGAb and TPOAb are found more frequently in Hashimoto’s thyroiditis, and the latter tend to correlate with thyroidal damage and lymphocytic inflammation(1, 2).

Individuals with AITD may be associated with other autoimmune diseases, of which type 1 diabetes mellitus (T1DM) is the most frequent(3-5). An increased risk of T1DM was reported in patients with AITD, the phenotype is referred to Autoimmune Polyendocrine
Syndrome Type II (APS II) when they occur in the same individual, and sometimes these two
diseases even coexist in the same family (6, 7). Both T1DM and AITD develop through a
complex interaction of genetic and environmental factors and result in autoimmune
destruction of the specific organs involving both humoral and cellular immune responses (1,
2, 4, 8, 9). Many studies have showed prevalence rate of thyroid autoantibodies range from
3.7-35% in T1DM patients, some of which suggested the associations between thyroid
autoantibodies and islet autoantibodies(10-14) . However, little work has been done about the
anti-islet autoimmune status in patients with AITD. As summarized in Additional File 1, the
prevalence rates of glutamic acid decarboxylase autoantibodies (GADA), islet cell
autoantibodies (ICA), insulinoma 2–associated autoantibodies (IA-2A) and insulin
autoantibodies (IAA) in patients with AITD were either slightly or significantly higher than
those in healthy controls, indicating there may be distinct immune status in different cohort.
Besides these classic islet autoantibodies (GADA, IA2-A, ICA and IAA), ZnT8A is the
recently identified new marker of autoimmunity in diabetes (15). Furthermore, the presence
of ZnT8A predisposes non-obese adult-onset diabetes patients to AITD(16) . However, there
has been no clinical study based on large population focus on ZnT8A in AITD patients
without T1DM.

In our study, we measured three islet autoantibodies, namely ZnT8A, GADA and IA-2A in
AITD patients without T1DM and also studied the relationship between islet autoantibodies
and thyroid autoantibodies. In addition, the prevalence rates among AITD, T1DM with AITD,
non-autoimmune thyroid disease (nAITD) patients and healthy controls were compared to
explore the anti-islet autoimmune condition. The data gained in this analysis are supposed to
provide a rationale for screening programs for active case-finding strategies in specialized
centers.
Research Design and Methods

Subjects

A total of 740 Chinese patients with AITD, but without T1DM (600 female and 140 male; aged 40.4 ± 14.0 years; body mass index [BMI] 22.44 ± 3.23 kg/m²) were recruited in our study. The AITD patients consisted of 377 patients with Graves’ disease and 363 patients with Hashimoto’s thyroiditis. Autoimmune thyroid diseases were diagnosed clinically by endocrinologists and confirmed by abnormal levels of thyroid hormones and autoantibodies to thyrotropin receptor, thyroid peroxidase, and/or thyroglobulin. 108 patients with T1DM and AITD (67 female and 41 male; aged 32.7±17.5 years; BMI 20.76 ± 3.42 kg/m²) were recruited in our study. Individuals with T1DM were diagnosed according to the diagnosis criteria of World Health Organization and American Diabetes Association. 172 patients (141 female and 31 male; aged 50.3±13.7 years; BMI 23.50 ± 3.40 kg/m²) with non-autoimmune thyroid disease (nAITD) such as subacute thyroiditis or thyroid nodules and 115 healthy controls (87 female and 28 male; aged 44.7±12.8 years; BMI 21.42 ± 2.56 kg/m²) were also included as control groups. Sera of patients with AITD or nAITD and healthy controls were obtained in the endocrinology department of the First Affiliated Hospital of Nanjing Medical University from October 2010 to September 2013, and sera of patients with T1DM and AITD were obtained at 26 centers in China from June 2010 to Oct 2012. The clinical characteristics of all subjects are summarized in Additional File 2.

Our study was approved by the appropriate ethical committees, and informed consent was obtained from all participants.

Islet autoantibody assay

Serum islet autoantibodies were measured by radioligand binding assay as previously described (16), using 35S-labeled glutamic acid decarboxylase-65 (GAD65),
protein-tyrosine-phosphatase-2 (IA-2) and zinc transporter 8 (ZnT8). Antibody levels were expressed as an immunoprecipitation index, which is defined as (sample – negative control)/ (positive control - negative control). The cut-off for positivity for GADA, IA-2A and ZnT8A was defined as a value above 0.048, 0.018, and 0.015 respectively, based on the 99th percentile of 102, 315 and 218 healthy control subjects (non-diabetic individuals without known autoimmune disease and no family history of diabetes). To compare the distribution and activity of three islet autoantibodies, islet autoantibody relative value was defined as islet autoantibody index/cut-off value.

Our laboratory has been validated in Islet Autoantibody Standardization Program 2020 with 60% study sensitivity and 100.0% study specificity for GADA, 70% study sensitivity and 100% study specificity for IA2A and 62% study sensitivity and 100.0% study specificity for ZnT8A.

**Thyroid function and antithyroid antibodies**

Free triiodothyronine (FT3), free tetraiodothyronine (FT4), thyroid-stimulating hormone (TSH), thyroglobulin autoantibodies (TgAb), and thyroid peroxidase autoantibodies (TPOAb) were all measured by immunochemiluminometric assays (Roche Diagnostics GmbH, Germany), while thyrotropin receptor autoantibodies (TRAb) was tested by radioimmunoassay (Cisbio Bioassays, France). Reference ranges for adults are TSH, 0.27–4.2 mU/L; FT3, 3.1–6.8 pmol/L; FT4, 12–22 pmol/L; TgAb < 115 IU/ml; TPOAb < 34 IU/ml; and TRAb, 0–1.5 IU/L.

**Statistical analysis**

Statistical analysis was performed with IBM SPSS 19.0 for windows. Results are shown as mean ± standard deviation or proportion (%). Unpaired Student’s t-test or ANOVA was
used to compare groups, and Kruskal-Wallis test was used for multigroup measurement data
with unequal variances. The difference between classified variables was tested using $\chi^2$ or
Fisher’s exact test if the expected number of subjects in any cell was less than five.
Multivariate linear regression model was used to analyze the correlation of measurement data.
Statistical significance was defined as $P<0.05$.

Results

1. Prevalence of thyroid autoantibodies and islet autoantibodies in AITD patients

Among 644 AITD patients with three thyroid autoantibodies detected at the time of
blood samples collection, the prevalence of TPOAb, TGAb and TRAb was 77.48%, 61.96%
and 49.22% respectively (Fig. 1A).

All of 740 AITD patients’ sera were measured three islet autoantibodies. A total of 177
(23.92%) AITD patients were positive for any of the three islet autoantibodies (Fig. 1B).

2. Comparison of prevalence and level of islet autoantibodies in different groups

The prevalence of islet autoantibodies in AITD patients was higher than that in healthy
controls (ZnT8A: 15.00% vs 1.74%, $P<0.05$; IA-2A: 4.19% vs 0%, $P<0.05$; GADA: 7.97%
vs 0.87%, $P<0.05$; $\geq 1$ islet Ab: 18.92% vs 2.61%, $P<0.05$), although lower than that in
patients with T1DM and AITD (ZnT8A: 15.00% vs 47.22%; IA-2A: 4.19% vs 44.44%;
GADA: 7.97% vs 74.07%; $\geq 1$ islet Ab: 18.92% vs 88.89%; $\geq 2$ islet Ab: 2.16% vs 50.00%,
all $P < 0.05$) (Fig. 2A, B, C and Additional File 3). Furthermore, in the groups of nAITD and
healthy controls, there were no subject with more than one islet autoantibody positive.

Islet autoantibody relative value (i.e. ZnT8A, GADA and IA-2A relative value) was
established to compare the level of islet autoantibodies. We confirmed significantly higher
means of three islet autoantibody relative values in the T1DM patients with AITD compared
with the AITD patients (all $P<0.01$). We also observed a significant increase of mean IA-2A
and GADA relative value in the AITD patients compared with healthy control subjects (p < 0.01), and a significantly higher mean GADA relative value in the AITD patients compared with the nAITD patients (p < 0.01). We even noticed that ZnT8A, IA-2A and GADA relative value in T1DM with AITD group were widely distributed and there were more markedly higher values than in other conditions (the highest were up to 80, 80 and 40, respectively), while the distributions in AITD, nAITD and healthy control group were relatively centralized (most of them were less than 5), except for some slightly high GADA relative values in AITD group and several high ZnT8A and IA2A relative values in AITD group and nAITD group (Fig.2D,E,F).

3. Comparison of prevalence and level of islet autoantibodies and thyroid autoantibodies between Graves disease and Hashimoto’s thyroiditis subjects

When AITD patients were divided into 2 subgroups, namely Graves’ disease (GD) and Hashimoto’s thyroiditis (HT), we observed significantly higher frequencies of either TPOAb or TGAb in the HT patients compared with the GD patients (TPOAb: 81.76% vs 72.89%; TGAb: 81.79% vs 44.67%, both P<0.01), while the prevalence of TRAb was significantly higher in the GD patients compared with the HT patients (82.70% vs 13.84%, P<0.01) (Additional File 4B). In addition, the distributions of TPOAb, TGAb and TRAb titers in the two subgroups had the similar tendency (Additional File 5 A,B,C). Nevertheless, it is remarkable to note that the prevalence of any islet autoantibody, at least one islet autoantibody and at least two islet autoantibodies did not differ significantly between subgroups (GD vs. HT: ZnT8A 13.79% vs 16.25%; IA-2A 4.51% vs 3.86%; GADA 8.49% vs 7.44%; ≥1 islet Ab: 23.34% vs 24.52%; ≥2 islet Ab: 3.18% vs 2.48%, all P>0.05) (Additional File 4A). Apart from this, three islet autoantibody relative values were also compared and no statistically significant differences were found between subgroups (all P>0.05, Additional File 5 D,E,F).
4. Characteristics of islet autoantibody – positive and – negative AITD patients

When AITD patients positive for TPOAb (>34 IU/ml) were divided into 2 subgroups according to the titer of TPOAb, namely a high-titer subgroup (≥600 IU/ml) and a low-titer subgroup (<600 IU/ml), so that there were 150 and 377 subjects, respectively. We observed increased prevalence of IA-2A, GADA and at least one islet autoantibody in the AITD patients with high-titer TPOAb (GADA: 12.67% vs 5.84%; IA-2A: 7.33% vs 2.39%, both p < 0.01; ≥1 islet Ab: 31.33% vs 22.55%, P<0.05). In addition, there was a trend for higher prevalence of ZnT8A in the AITD patients with high-titer TPOAb compared with those with low-titer TPOAb, but this difference did not reach statistical significance (19.33% vs 15.38%, P>0.05) (Fig.3A). The level of three islet autoantibodies was further analyzed between subgroups, but we only observed a higher mean IA-2A relative value in the high-titer TPOAb patients with the borderline significance (P=0.046, Additional File 6). When it comes to the comparison of the prevalence for high-titer TPOAb between islet autoantibody – positive and – negative AITD patients, a larger proportion of patients with high-titer TPOAb was found in the islet autoantibody – positive AITD patients except for ZnT8A-positive patients (Table 1).

However, the prevalence for any islet autoantibody as well as at least one islet autoantibody differ little with the titer of TPOAb or TGAb increased (Fig.3B,C), and we did not find statistically significant differences in either TPOAb or TGAb positive rate between the AITD patients with islet autoantibody – positive and – negative, either. Besides, there were no statistically significant differences in sexual proportion, subtypes of disease, age, duration, prevalence of type 2 diabetes mellitus (T2DM), antithyroidal treatment, and level of either TSH or FT4 between islet autoantibody – positive and – negative AITD patients (Table 1), except for a borderline statistical significance (P = 0.048) in BMI between ZnT8A – positive and – negative AITD patients, and statistically increases in BMI and TRAb positive rate between IA-2A – positive and – negative AITD patients (Table 1). These findings suggest
an increase level of islet autoimmunity independent of subtypes of disease, gender, age, duration, concurrent type 2 diabetes mellitus, anti-thyroidal treatment, TPOAb or TGAb positivity and thyroid function.

(please put table1 here)

In the analysis of multivariable linear regression, we found that ZnT8A relative value was positively correlated with GADA relative value ($\beta=0.352$, $P<0.01$) and TPOAb titer ($\beta=0.002$, $P<0.01$), and GADA relative value was also positively correlated with ZnT8A relative value ($\beta=0.183$, $P<0.01$) (Additional File 7). Apart from this, IA-2A relative value showed no association with any of above.

Discussion

Here we are the first to show that the prevalence of ZnT8A was as high as 15.00% in the AITD patients, and as expected, was significantly higher than that in the healthy controls. It was also a novel finding that the prevalence rate of ZnT8A was much higher than that of GADA (7.97%) in the AITD population, as the latter in the previous studies was the highest (17-21). Previous evidences have already shown that ZnT8A is frequent in a lot of endocrine or autoimmune disorders. As in the report from Wenzlau et al.(15), ZnT8A occurred in 60-80% of new-onset T1DM, in less than 2% of controls, in less than 3% of T2DM and in up to 30% of non-diabetic patients with other autoimmune disorders with a T1DM association. In accordance with these findings, our study observed that the prevalence of ZnT8A in AITD was significantly lower than that in T1DM, but was still slightly higher or significantly higher than that in nAITD or healthy subjects. Rydzewska et al. (22) held the opinion that the existence of ZnT8A in AITD patients may play an important role in the immune bystander responses towards ZnT8 protein expressed on thyroid. To further investigate that, thyroidectomy species have been collected from patients with thyroid nodular goiter and GD
and dealt with Immunohistochemical staining. The strong ZnT8 staining could been observed in almost all of the thyroid follicular cells and some of the cytoplasm and the perinuclear area of the hyperplastic C cells. In accordance with the observations mentioned before, ZnT8 was identified to be a major autoantigen in human type 1 diabetes and localized into insulin secretory granules (15, 23), and it also expressed in other secretory cell types of murine like pancreatic α islet cells, thyroid cubical cells and adrenal gland cortex cells (24), so our data further confirm the widespread role of ZnT8 in the endocrine system (15, 24, 25). In addition, we observed significant differences in the level of ZnT8A between T1DM with AITD and AITD, while there were no statistical differences between AITD and nAITD or healthy controls. These results can be explained by the non-specificity of ZnT8A appearing in the AITD patients without T1DM. Interesting, despite the finding that no statistical differences were observed in the prevalence rate and level of ZnT8A regarding comparison on TPOAb in our study, we still found an association among the level of ZnT8A, GADA and TPOAb. Given that Rogowicz-Frontczak et al. (16) revealed an association among positive ZnT8A, GADA and positive titer of TPOAb in LADA, and Jonsdottir et al. (11) also demonstrated an association between two thyroid autoantibodies (TPOAb and TGAb) and ZnT8A or GADA positivity in a large population of newly diagnosed T1DM children, taken together we conclude that there is a potential link between thyroid autoimmunity and islet autoimmunity in autoimmune thyroid disease. Longitudinal studies are necessary to determine the predict value of both GADA and ZnT8A positive in patients with AITD for developing T1DM.

Measurements of GADA and IA-2A are recommended for initial confirmation of the suspected diagnosis of T1DM or for the prediction of T1DM in research settings (26). Our prevalence of either GADA or IA-2A was similar to findings in the previous studies (18, 19, 27-29). While there was a significantly lower frequency and level of either GADA or IA-2A in the AITD patients compared with that in the T1DM patients, the results were still
significant higher than in the healthy subjects, thus partly confirmed the findings on GADA of Kawasaki et al. (19). Take into consideration the early study from Kawasaki et al. (30) which demonstrated that the level of GADA in T1DM with AITD were found to be significantly higher than in patients without AITD, and the recent Chinese study revealing the high level of GADA to be a strong predictor of the development of thyroid autoimmunity in patients with autoimmune diabetes (31), as well as the finding of Lethagen et al. (32) that GADA positivity could be a marker of subclinical insulitis in non-diabetic patients with autoimmune thyroiditis, and the strong connection which Brorsson et al. (9) figured out that GADA is related to both increasing age and human leukocyte antigen (HLA) DQ2/DR3, we conclude that the presence of GADA may be a marker of concurrent or successive thyroid autoimmunity and islet autoimmunity. Pilia et al. (18) observed that IA-2A was significantly prevalent in Sardinian children with autoimmune thyroiditis, which is consistent with our results to some degree, however, their prevalence of GADA showed no significant differences compared with healthy controls. Since the study populations were entirely composed of Sardinian children and adolescents and the patients were only with autoimmune thyroiditis, which may explain the discordance with our results. Remarkably, despite our findings that the positive rate of either GADA or IA-2A did not vary much with TPOAb titer increasing, we observed a significant higher frequency of GADA and IA-2A in the AITD patients with high-titer TPOAb, and also a higher prevalence of high-titer TPOAb in the GADA- or IA-2A- positive patients, therefore we infer that AITD patients, not only those with Hashimoto’s thyroiditis, with high-titer TPOAb tend to have more islet autoimmunity. Besides, to our knowledge, it is the first time that a statistically higher TRAb positive rate was found in IA-2A-positive AITD patients compared with IA-2A-negative AITD patients, so further studies are demanded to elucidate their relationship.

Our large cohort made it possible to compare the prevalence of three islet autoantibodies
between populations with AITD without T1DM and T1DM with AITD, nAITD or healthy
subjects, thereby allowing us to determine the islet autoimmunity in AITD. Islet
autoantibodies were measured by a sensitive radioligand binding assay, which was confirmed
by our laboratory performance characteristics from Islet Autoantibody Standardization
Program certification of 2020 workshop participation. Moreover, although other studies have
shown that patients with AITD are at increased risk of developing T1DM (18, 33), which
were mainly based on the follow-up of one autoantibody. It is believed that the presence of
any one single autoantibody appears not to be of predictive value for the disease (34-36).
Therefore, we infer that the AITD patients with two or more islet autoantibodies positive,
especially those also with high-titer TPOAb, are at high risk of progressing to T1DM.
However, limited to that our study was cross-sectional and case-control, there was no
long-term follow up and the other two islet autoantibodies were not measured, thus the
functional changes of islet β cells and anti-islet autoimmune status remains to be clarified in
future longitudinal studies. Besides, the discordance of sexual proportion and age between
patients with AITD and T1DM as well as multiple statistical comparisons may decrease the
statistical power.

Conclusions

In conclusion, an increased prevalence of ZnT8A as well as a relatively high prevalence
of islet autoimmunity was found in patients with autoimmune thyroid disease. It indicates
there is a potential link between thyroid autoimmunity and islet autoimmunity. The presence
of GADA may be a marker of concurrent or successive thyroid autoimmunity and islet
autoimmunity, and patients with high-titer TPOAb tend to have more islet autoimmunity in
autoimmune thyroid disease. We suggest, therefore, patients with autoimmune thyroid disease
who also have a high-titer TPOAb, may need screening for blood glucose and islet
autoantibodies, and those found with two or more islet autoantibodies positive may need
long-term follow-up for islet dysfunction.

List of abbreviations

- AITD: Autoimmune Thyroid Disease
- nAITD: non-Autoimmune Thyroid Disease
- GD: Graves’ Disease
- HT: Hashimoto’s Thyroiditis
- T1DM: Type 1 Diabetes Mellitus
- T2DM: Type 2 Diabetes Mellitus
- ZnT8A: Zinc Transporter 8 Autoantibodies
- GADA: Glutamic Acid Decarboxylase Autoantibody
- IA-2A: Protein Tyrosine Phosphatase-2 Autoantibody
- IAA: Insulin Autoantibody
- ICA: Islet Cell Autoantibody
- TPOAb: Thyroid Peroxidase Antibody
- TRAb: Thyrotropin Receptor Antibody
- TGAb: Thyroglobulin Antibody
- APS: Autoimmune Polyendocrine Syndromes
- BMI: Body Mass Index
- TSH: Free Tetraiodothyronine
- FT3: Free Triiodothyronine
- FT4: Thyroid-stimulating Hormone
- HLA: Human Leukocyte Antigen
Declarations

Ethics approval and consent to participate
The experimental protocol was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University and conformed to the provisions of the Declaration of Helsinki (Ethical approval No. 2010-SR-021).

Consent for publication
Not applicable.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests
The authors declare that they have no competing interests.

Funding
This work is supported by the grant from the National Natural Science Foundation of China (No.81270897), the Jiangsu Provincial Special Program of Medical Science (BL2012026) and the Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.

Authors' contributions
C.Y. and Y.J.N designed and wrote the manuscript and performed most experiments. Y.T. and Z.X.Q. contributed to design of the study and reviewed and edited the manuscript. Y.L.P. help to take control of the autoantibodies assay. All authors reviewed and take full responsibility for the contents of the manuscript. Y.T is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Acknowledgements

We express our sincere appreciation to George Eisenbarth, John Hutton and Howard Davidson (Barbara Davis Center of Childhood Diabetes, University of Colorado, CO, USA) for their tutoring and guidance.

References


Figure 1. Frequency of islet autoantibodies and thyroid autoantibodies in autoimmune thyroid diseases subjects.

**Figure 1A.** Frequency of thyroid autoantibodies is shown in 644 patients with autoimmune thyroid diseases. Of these, 616 (95.65%) were positive for at least one thyroid autoantibody.

**Figure 1B.** Frequency of islet autoantibodies is shown in 740 patients with autoimmune thyroid diseases. Of these, 177 (23.92%) were positive for at least one islet autoantibody.
Figure 2. Frequency of islet autoantibodies in T1DM with AITD, AITD, nAITD and HC subjects.
Figure 3. Frequency of islet autoantibodies in AITD subjects with high titer TPOAb and low titer TPOAb.
Table 1. Clinical characteristics of eight subgroups of autoimmune thyroid diseases subjects.

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>ZnT8A+ (n=111)</th>
<th>ZnT8A- (n=629)</th>
<th>GADA+ (n=59)</th>
<th>GADA- (n=681)</th>
<th>IA-2A+ (n=31)</th>
<th>IA-2A- (n=709)</th>
<th>Islet Ab+ (n=177)</th>
<th>Islet Ab- (n=563)</th>
<th>P_a</th>
<th>P_b</th>
<th>P_c</th>
<th>P_d</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (female/male)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>(n)</td>
<td>95/16</td>
<td>505/124</td>
<td>49/10</td>
<td>551/130</td>
<td>27/4</td>
<td>573/136</td>
<td>147/30</td>
<td>453/110</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Disease (GD/HT)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td></td>
<td>52/59</td>
<td>325/304</td>
<td>32/27</td>
<td>345/336</td>
<td>17/14</td>
<td>360/349</td>
<td>88/89</td>
<td>289/274</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td></td>
<td>42 (9-79)</td>
<td>40.5 (10-76)</td>
<td>39 (16-65)</td>
<td>41 (9-79)</td>
<td>43 (20-65)</td>
<td>41 (9-79)</td>
<td>41.5 (9-79)</td>
<td>41 (10-76)</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Duration (years)</td>
<td>2.78±4.85</td>
<td>2.54±4.82</td>
<td>2.36±4.23</td>
<td>2.59±4.87</td>
<td>2.87±4.10</td>
<td>2.56±4.85</td>
<td>2.66±4.37</td>
<td>2.55±4.96</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>BMI (Kg/m²)</td>
<td>21.85±2.92</td>
<td>22.54±3.27</td>
<td>22.63±3.98</td>
<td>22.42±3.15</td>
<td>20.85±2.18</td>
<td>22.51±3.25</td>
<td>22.12±3.24</td>
<td>22.54±3.22</td>
<td>0.048</td>
<td>&gt;0.05</td>
<td>&lt;0.01</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>T2DM (n%)</td>
<td>7 (6.48%)</td>
<td>26 (4.19%)</td>
<td>3 (5.08%)</td>
<td>30 (4.48%)</td>
<td>0 (0.00%)</td>
<td>33 (4.73%)</td>
<td>9 (5.17%)</td>
<td>24 (4.33%)</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>TPOAb+ (n%)</td>
<td>87 (81.31%)</td>
<td>441 (76.56%)</td>
<td>41 (73.21%)</td>
<td>487 (77.67%)</td>
<td>21 (70.00%)</td>
<td>507 (77.64%)</td>
<td>133 (77.78%)</td>
<td>395 (77.15%)</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>High-titer TPOAb (n%)</td>
<td>29 (33.33%)</td>
<td>121 (27.50%)</td>
<td>19 (46.34%)</td>
<td>131 (26.95%)</td>
<td>11 (55.00%)</td>
<td>139 (27.42%)</td>
<td>47 (35.61%)</td>
<td>103 (26.08%)</td>
<td>&gt;0.05</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Subgroup</td>
<td>ZnT8A+ (n=111)</td>
<td>ZnT8A- (n=629)</td>
<td>GADA+ (n=59)</td>
<td>GADA- (n=681)</td>
<td>IA-2A+ (n=31)</td>
<td>IA-2A- (n=709)</td>
<td>Islet Ab+ (n=177)</td>
<td>Islet Ab- (n=563)</td>
<td>P_a</td>
<td>P_b</td>
<td>P_c</td>
<td>P_d</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------</td>
<td>----------------</td>
<td>---------------</td>
<td>---------------</td>
<td>---------------</td>
<td>---------------</td>
<td>------------------</td>
<td>------------------</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>TGAb+ (n%)</td>
<td>73 (68.22%)</td>
<td>352 (62.19%)</td>
<td>34 (62.96%)</td>
<td>391 (63.17%)</td>
<td>15 (51.72%)</td>
<td>410 (63.66%)</td>
<td>109 (64.88%)</td>
<td>316 (62.57%)</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>TRAb+ (n%)</td>
<td>48 (46.15%)</td>
<td>278 (50.09%)</td>
<td>29 (53.70%)</td>
<td>297 (49.09%)</td>
<td>21 (70.00%)</td>
<td>305 (48.49%)</td>
<td>84 (50.60%)</td>
<td>242 (49.09%)</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&lt;0.05</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Drug (n%)</td>
<td>76 (68.47%)</td>
<td>411 (65.34%)</td>
<td>32 (54.24%)</td>
<td>455 (66.81%)</td>
<td>23 (74.19%)</td>
<td>464 (65.44%)</td>
<td>119 (67.23%)</td>
<td>368 (65.36%)</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>TSH (n)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;22 miu/l</td>
<td>28</td>
<td>136</td>
<td>8</td>
<td>156</td>
<td>6</td>
<td>158</td>
<td>40</td>
<td>124</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12-22 miu/l</td>
<td>34</td>
<td>199</td>
<td>16</td>
<td>217</td>
<td>7</td>
<td>226</td>
<td>51</td>
<td>182</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>&lt;12 miu/l</td>
<td>46</td>
<td>263</td>
<td>33</td>
<td>276</td>
<td>17</td>
<td>292</td>
<td>82</td>
<td>227</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;4.2 pmol/l</td>
<td>32</td>
<td>184</td>
<td>24</td>
<td>192</td>
<td>11</td>
<td>205</td>
<td>59</td>
<td>157</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FT4 (n)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.27-4.2 pmol/l</td>
<td>57</td>
<td>319</td>
<td>27</td>
<td>349</td>
<td>16</td>
<td>360</td>
<td>87</td>
<td>289</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>&lt;0.27 pmol/l</td>
<td>15</td>
<td>89</td>
<td>6</td>
<td>98</td>
<td>3</td>
<td>101</td>
<td>23</td>
<td>81</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 Pa, ZnT8A+ vs ZnT8A-; P_b, GADA+ vs GADA-; P_c, IA-2A+ vs IA-2A-; P_d, Islet Ab+ vs Islet Ab-. ZnT8A+, ZnT8A positive; ZnT8A-, ZnT8A negative; GADA+, GADA positive; GADA-, GADA negative; IA-2A+, IA2A positive; IA-2A-, IA2A negative; Islet Ab+, at least one islet autoantibody positive; Islet Ab-, all islet autoantibodies negative.
Additional File 1 The published studies investigated prevalence of islet autoantibodies in AITD patients.

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Ref.</th>
<th>Study population</th>
<th>GADA (AITD/controls)(%)</th>
<th>ICA (AITD/controls)(%)</th>
<th>IA2A (AITD/controls)(%)</th>
<th>IAA (AITD/controls)(%)</th>
<th>ZnT8A (AITD/controls)(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pilia</td>
<td>2011</td>
<td>25</td>
<td>236 non-diabetic Sardinian children and adolescents with autoimmune thyroiditis; 949 healthy controls</td>
<td>5.09/3.79</td>
<td>-</td>
<td>3.39/1.16</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Moriguchi</td>
<td>2011</td>
<td>29</td>
<td>866 Japanese AITD patients (diabetics included); 282 controls</td>
<td>5.8/2.1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sallorenzo</td>
<td>2017</td>
<td>31</td>
<td>324 AITD patients (non-diabetic patients); 93 healthy controls</td>
<td>4.9/0</td>
<td>-</td>
<td>0.7/0</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Maugendre</td>
<td>1997</td>
<td>48</td>
<td>600 Caucasian patients with recently diagnosed Graves’ disease (10 diabetics and 590 non-diabetics)</td>
<td>4.9 (non-diabetic)</td>
<td>4 (non-diabetic)</td>
<td>3.8/0</td>
<td>7.2</td>
<td>7.6/3.4</td>
</tr>
<tr>
<td>Kawasaki</td>
<td>1995</td>
<td>28</td>
<td>288 non-diabetic AITD patients; 235 controls</td>
<td>6.3/0.9</td>
<td>0/0</td>
<td>-</td>
<td>3.8/0</td>
<td>-</td>
</tr>
<tr>
<td>Yamaguchi</td>
<td>1991</td>
<td>17</td>
<td>316 AITD patients (T1DM included); 53 T1DM patients; 144 healthy control subjects</td>
<td>7.6/0.7</td>
<td>-</td>
<td>-</td>
<td>7.2</td>
<td>7.6/3.4</td>
</tr>
<tr>
<td>Ng</td>
<td>1990</td>
<td>19</td>
<td>97 non-diabetic AITD patients</td>
<td>-</td>
<td>0</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Jonsdottir</td>
<td>2019</td>
<td>33</td>
<td>278 patients with newly diagnosed GD</td>
<td>8.7</td>
<td>3.2</td>
<td>7.2</td>
<td>9.2</td>
<td>3.4/3.4</td>
</tr>
<tr>
<td>Rydzewska</td>
<td>2019</td>
<td>54</td>
<td>44 children with GD; 65 children with HT; 199 children with T1DM with or without AITDs; 58 control children</td>
<td>7.3/3.4</td>
<td>5.5/0</td>
<td>3.7/0</td>
<td>9.2/3.4</td>
<td>7.6/3.4</td>
</tr>
</tbody>
</table>
Additional File 2 Clinical characteristics of type 1 diabetes mellitus with autoimmune thyroid disease (T1DM with AITD), autoimmune thyroid diseases (AITD), non-autoimmune thyroid diseases (nAITD) and health control (HC) subjects.

<table>
<thead>
<tr>
<th>Groups</th>
<th>AITD (n=740)</th>
<th>T1DM with AITD (n=108)</th>
<th>nAITD (n=172)</th>
<th>HC (n=115)</th>
<th>P</th>
<th>P_a</th>
<th>P_b</th>
<th>P_c</th>
</tr>
</thead>
<tbody>
<tr>
<td>sex (female/male)</td>
<td>600/140</td>
<td>67/41</td>
<td>141/31</td>
<td>87/28</td>
<td></td>
<td>&lt;0.05*</td>
<td></td>
<td>&gt;0.05*</td>
</tr>
<tr>
<td>age (years)</td>
<td>40.4±14.0</td>
<td>32.7±17.5</td>
<td>50.3±13.7</td>
<td>44.7±12.8</td>
<td></td>
<td>&lt;0.05†</td>
<td>&lt;0.01§</td>
<td>&lt;0.01§</td>
</tr>
<tr>
<td>duration (years)</td>
<td>2.57±4.82</td>
<td>0.89±2.55a</td>
<td>1.10±2.72</td>
<td>-</td>
<td></td>
<td>&lt;0.05‡</td>
<td>&lt;0.01§</td>
<td>&lt;0.01§</td>
</tr>
<tr>
<td>BMI (Kg/m²)</td>
<td>22.44±3.23</td>
<td>20.76±3.42</td>
<td>23.50±3.40</td>
<td>21.42±2.56</td>
<td>&lt;0.05‡</td>
<td>&lt;0.01§</td>
<td>&lt;0.01§</td>
<td>&lt;0.01§</td>
</tr>
</tbody>
</table>

P_a: AITD vs T1DM with AITD, P_b: AITD vs nAITD, P_c: AITD vs HC, * χ² analysis, † ANOVA, ‡ Kruskal-Wallis test, § independent-samples T Test, a represents the duration when T1DM and AITD co-exist.
Additional File 3 Prevalence of at least one or two islet autoantibodies in type 1 diabetes mellitus with autoimmune thyroid disease (T1DM with AITD), autoimmune thyroid diseases (AITD), non-autoimmune thyroid diseases (nAITD) and health control (HC) subjects.*P<0.05, NS: not significant.
Additional File 4 Prevalence of islet autoantibodies and thyroid autoantibodies in Graves’ disease (GD) and Hashimoto’s thyroiditis (HT) subjects. **P<0.01, NS: not significant.
Additional File 5 Distributions of islet autoantibodies and thyroid autoantibodies in Graves’ disease (GD) and Hashimoto’s thyroiditis (HT) subjects.
Additional File 6 Distribution of islet autoantibody relative values in TPOAb-positive AITD subjects with high-titer TPOAb (H-TPOAb) and low-titer TPOAb (L-TPOAb).
## Additional File 7 Multivariable linear regression

<table>
<thead>
<tr>
<th>Independent variable</th>
<th>ZnT8A relative value</th>
<th>GADA relative value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β</td>
<td>P value</td>
</tr>
<tr>
<td>ZnT8A relative value</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>GADA relative value</td>
<td>0.352</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>IA-2A relative value</td>
<td>0.006</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Duration</td>
<td>-0.019</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>BMI</td>
<td>0</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>FT3</td>
<td>-0.018</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>FT4</td>
<td>0.017</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>TSH</td>
<td>0.003</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>TPOAb</td>
<td>0.002</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>TGAb</td>
<td>0</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>TRAb</td>
<td>-0.001</td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>